Seeing Lung Cancer with a Special Dye During Bronchoscopy
Part of Cancer, Lungs & breathing clinical trials.
This study tests a special dye attached to durvalumab (a cancer drug) to see if it can light up tumors in the lungs during a bronchoscopy. It will help doctors see if the drug reaches the cancer cells and may guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III non-small cell lung cancer that can't be surgically removed.
- You have finished chemotherapy and radiation therapy together.
- You are healthy enough for a light sedation procedure (bronchoscopy) where the doctor can look inside your airways.
- You are eligible to receive durvalumab (Imfinzi) as part of your standard care.
- You have a tumor that can be reached with a bronchoscope for a small tissue sample.
- You are at least 18 years old and able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
This trial studies whether adding durvalumab (an immune therapy) to standard chemoradiation before surgery can improve outcomes for people with stage III, resectable lung cancer. It aims to help shrink the tumor and improve chances of successful treatment.
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
Hear when a new Stage III Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.